NASDAQ:IDYA
IDEAYA Biosciences Inc. Stock News
$37.71
-0.740 (-1.92%)
At Close: May 24, 2024
IDEAYA Biosciences, Inc. (Nasdaq:IDYA) is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using mole
IDEAYA Biosciences, Inc. Reports First Quarter 2020 Financial Results and Provides Business Update
10:00am, Tuesday, 12'th May 2020
IDEAYA Biosciences, Inc. (Nasdaq:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecu
Molecular Diagnostics Market By Key Players, Deployment Type, Applications, Vertical, and Region – Forecast 2026
09:48am, Monday, 11'th May 2020
May 11, 2020 (AmericaNewsHour) --
Global Molecular Diagnostics Market is valued approximately at USD 8.4 billion in 2019 and is anticipated to grow with a...
ARK Genomic Revolution Multi-Sector ETF: An Overbought But Promising Niche Play
02:10pm, Friday, 08'th May 2020
I am neutral on ARKG, an exciting, niche biotech ETF that currently looks overbought on the charts. I expect investor interest in this space to stay elevated on
May 05, 2020 Xherald --
Veterinary Reference Laboratory (VRL) Market report will make detailed analysis mainly on in-depth research on the development...
Roche Q1 Sales Call Key Takeaways
12:39pm, Tuesday, 28'th Apr 2020
We highlight main points from Roche Q1 conference call and summarize key takeaways for investors. Pharma is showing resilience in the face of intensive biosimil
AstraZeneca's Lynparza shows further promise in prostate cancer study
07:21am, Friday, 24'th Apr 2020
A cancer drug from AstraZeneca and Merck helped men with advanced prostate cancer and certain genetic mutations live longer in a late-stage study investigating its effectiveness, the British company s
'A disaster': Roche CEO's verdict on some COVID-19 antibody tests
07:35pm, Wednesday, 22'nd Apr 2020
Some blood tests being marketed to tell people if they have had the new coronavirus are a "disaster", Roche Chief Executive Severin Schwan said on Wednesday as he prepares to launch the drugmaker's ow
Roche décoiffe les attentes au premier trimestre 2020
04:11pm, Wednesday, 22'nd Apr 2020
La croissance a été alimentée par la principale division Pharmaceuticals, dont les revenus ont progressé de 3% à 12,26 milliards. L'action a clôturé en nette hausse.
IDEAYA Biosciences Announces Addition of Julie Patel as Vice President, Human Resources, Enhancing its Leadership Team
10:00am, Tuesday, 21'st Apr 2020
IDEAYA Biosciences, Inc. (Nasdaq:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecu
Fly Intel: Top five analyst initiations JAZZ;CLAR;IMRA;IDYA;SLAB
02:42pm, Monday, 06'th Apr 2020
Fly Intel: Top five analyst initiations JAZZ CLAR IMRA IDYA SLAB
Wall Street Analysts Are Bullish on Top Healthcare Picks
11:16am, Monday, 06'th Apr 2020
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on InspireMD (NSPR), IDEAYA Biosciences (IDYA) and Capricor
